Cardiac contractility modulation for the treatment of moderate to severe HF

References

• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017;136(6):e137–e161.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• JJV M, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Daubert C, Behar N, Martins RP, et al. Avoiding non-responders to cardiac resynchronization therapy: a practical guide. Eur Heart J. 2017;38(19):1463–1472.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation. JACC Heart Fail. 2018 Oct;6(10):874–883. Epub 2018 May 10. PMID: 29754812
   PubMed Web of Science ®Google Scholar
• Cantillon DJ, Exner DV, Badie N, et al. Complications and health care costs associated with transvenous cardiac pacemakers in a nationwide assessment. JACC Clin Electrophysiol. 2017 Nov;3(11):1296–1305. . Epub 2017 Aug 30. PMID: 29759627.
   PubMedGoogle Scholar
• Wiegn P, Chan R, Jost C, et al. Safety, performance, and efficacy of cardiac contractility modulation delivered by the 2-lead optimizer smart system: the FIX-HF-5C2 study. Circ Heart Fail. 2020;13(4):e006512.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Nademanee K, Volosin K, et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011;17(9):710–717.
   PubMed Web of Science ®Google Scholar
• Witte K, Hasenfuss G, Kloppe A, et al. Cost-effectiveness of a cardiac contractility modulation device in heart failure with normal QRS duration. ESC Heart Fail. 2019;6(6):1178–1187.
   PubMed Web of Science ®Google Scholar
• Wood EH, Heppner RL, Weidmann S. Inotropic effects of electric currents. I. Positive and negative effects of constant electric currents or current pulses applied during cardiac action potentials. II. Hypotheses: calcium movements, excitation-contraction coupling and inotropic effects. Circ Res. 1969;24(3):409–445.
   PubMed Web of Science ®Google Scholar
• Lyon AR, Samara MA, Feldman DS. Cardiac contractility modulation therapy in advanced systolic heart failure [published correction appears in Nat Rev Cardiol. 2014 Apr;11(4):188]. Nat Rev Cardiol. 2013;10(10):584–598.
   PubMed Web of Science ®Google Scholar
• Butter C, Rastogi S, Minden HH, et al. Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure. J Am Coll Cardiol. 2008;51(18):1784–1789.
   PubMed Web of Science ®Google Scholar
• Imai M, Rastogi S, Gupta RC, et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol. 2007;49(21):2120–2128.
   PubMed Web of Science ®Google Scholar
• Headrick JP, Willis RJ. Relation between the O2 supply:demand ratio, MVO2, and adenosine formation in hearts stimulated with inotropic agents [published correction appears in Can J Physiol Pharmacol 1990 Jun;68(6):752]. Can J Physiol Pharmacol. 1990;68(1):110–118.
   PubMed Web of Science ®Google Scholar
• Overgaard CB, Dzavík V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118(10):1047–1056.
   PubMed Web of Science ®Google Scholar
• Yu CM, Chan JY, Zhang Q, et al. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. JACC Cardiovasc Imaging. 2009;2(12):1341–1349.
   PubMed Web of Science ®Google Scholar
• Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29(8):1019–1028.
   PubMed Web of Science ®Google Scholar
• Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure [published correction appears in Am Heart J. 2011 Jun;161(6):1220]. Am Heart J. 2011;161(2):329–337.e3372.
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845–1853.
   PubMed Web of Science ®Google Scholar
• Müller D, Remppis A, Schauerte P, et al. Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction. Clin Res Cardiol. 2017;106(11):893–904.
   PubMed Web of Science ®Google Scholar
• Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. Eur J Heart Fail. 2019;21(9):1103–1113.
   PubMed Web of Science ®Google Scholar
• Tracy CM, Epstein AE, et al.; 2012 Writing Group Members. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Thorac Cardiovasc Surg. 2012;144(6):e127–e145.
   PubMedGoogle Scholar
• Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2020;76(1):1–13.
   PubMed Web of Science ®Google Scholar